Global Irritable Bowel Syndrome (IBS) market will reach 8650 million US$ by the end of 2025

Publisher: QYResearch

Published Date: 2018/11/30

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.

Currently, the IBS treatment market is naïve and underpenetrated, with 4 products indicated for IBS in the market. These include the IBS-C therapies, Amitiza (lubiprostone, Sucampo/Takeda) and Linzess (linaclotide, Ironwood/Allergan/Astellas); and the IBS-D therapies, Lotronex (Sebela Pharmaceuticals) and Irribow (ramosetron, Astellas). Antidepressants and antibiotics (mainly Xifaxan [rifaximin], Valeant) are also used off-label to treat IBS.

The IBS treatment market is characterized by significant unmet needs, which include the need for products with improved efficacy, products for the treatment of the IBS-D and IBS-M subtypes, and products that effectively address IBS symptoms, such as abdominal pain and bloating, as well as the requirement for the improved diagnosis of IBS. As a result, there are significant opportunities in the uncrowded IBS therapeutics market.

The global Irritable Bowel Syndrome (IBS) market is valued at 2640 million US$ in 2017 and will reach 8650 million US$ by the end of 2025, growing at a CAGR of 16.0% during 2018-2025.

Click to view the full report: https://www.qyresearch.com/index/detail/72527/global-irritable-bowel-syndrome-ibs-market

This article was first released by QYResearch, if reproduced, please indicate the source.

Marketing: sales@qyresearchglobal.com

Media Contact: press@qyresearch.com